Exercise After Prostate Cancer Diagnosis

  • Daniel Santa Mina
  • Paul Ritvo
  • Roanne Segal
  • N. Culos-Reed
  • Shabbir M.H. Alibhai


PCa is the second most commonly diagnosed cancer in men. Though often curable or treatable with an excellent long-term survival, many therapeutic options reduce health-related QoL. Exercise and regular PA have been demonstrated as beneficial throughout the continuum of the disease. Clinically important benefits have been observed particularly during the active treatment phase. Several recent intervention trials have investigated the effects of different exercise modalities (e.g., aerobic exercise, resistance training) during treatment on patient health-related QoL with promising results. Given the observed benefits, the issue of exercise adherence is becoming the focal point of studies as researchers strive to initiate a chronic health behavior change of increased PA to maintain exercise benefits beyond the acute intervention phase. This chapter reviews the current body of literature on exercise during PCa treatment and provides recommendations for future studies, implications for clinical practice, and preliminary recommendations for exercise prescription.


Resistance Training Aerobic Exercise Exercise Intervention Booster Session Exercise Adherence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society, Cancer Facts & Figures 2008, 1–72, 2008.Google Scholar
  2. 2.
    Canadian Cancer Society/National Cancer Institute of Canada. (2008) Canadian Cancer Statistics, pp. 1–72.Google Scholar
  3. 3.
    Quinn M, Babb P. (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. Br J Urol Int 90:162–173.Google Scholar
  4. 4.
    Hsing A, Tsao WL, Devesa SS. (1999) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85:60–67.CrossRefGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V.I. 2008, 1–44, 2008.Google Scholar
  6. 6.
    Fowler FJ, Barry MJ, Lu-Yao G, Wasson J, Roman A, Wennberg J. (1995) Effect of radical prostatectomy for prostate cancer on patient quality of life: Results from a medicare survey. Urology 45:1007–1115.CrossRefPubMedGoogle Scholar
  7. 7.
    Moore KN, Estey A. (1999) The early post-operative concerns of men after radical prostatectomy. J Adv Nurs 29:1121–1129.CrossRefPubMedGoogle Scholar
  8. 8.
    Haythornthwaite JA, Raja SN, Fisher B, Frank SM, Brendler CB, Shir Y. (1998) Pain and quality of life following radical retropubic prostatectomy. J Urol 160:1761–1764.CrossRefPubMedGoogle Scholar
  9. 9.
    Meuleman E. (2003) Erectile function after radical prostatectomy: a review. Eur Urol 43:95–102.CrossRefPubMedGoogle Scholar
  10. 10.
    Peschel RE, Colberg JW. (2003) Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4:233–241.CrossRefPubMedGoogle Scholar
  11. 11.
    Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. (1995) Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273:129–135.CrossRefPubMedGoogle Scholar
  12. 12.
    Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. (1996) Waning sexual function – the most important disease-specific distress for patients with prostate cancer. Br J Cancer 73:1417–1421.PubMedCrossRefGoogle Scholar
  13. 13.
    Klotz L, Kiberl AS, Sanda M, Thompson I, Clarke N (2008) Surveillance Therapy Against Radical Treatment Trial (START), September 5, 2008.Google Scholar
  14. 14.
    Kennedy TJ, Sonneland AM, Marlett MM, Troup RH. (1992) Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J Urol 147:891–893.PubMedGoogle Scholar
  15. 15.
    Macfarlane MT, Abi-Aad A, Stein A, Danella J, Belldegrum A, deKernion JB. (1993) Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 150:132–134.PubMedGoogle Scholar
  16. 16.
    Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP. (1993) Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149:779–782.PubMedGoogle Scholar
  17. 17.
    Strum SE, McDermed JE, Scholz MC, Johnson H, Tisman G. (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933–941.PubMedGoogle Scholar
  18. 18.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163: 181–186.CrossRefPubMedGoogle Scholar
  19. 19.
    Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599–603.CrossRefPubMedGoogle Scholar
  20. 20.
    Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656–3661.CrossRefPubMedGoogle Scholar
  21. 21.
    Alibhai SMH, Gogov S, Allibhai Z. (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60:201–215.CrossRefPubMedGoogle Scholar
  22. 22.
    Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G, Szumacher E, Loblaw A, Cheung P, Woo T. (2005) Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys 62:719–724.CrossRefPubMedGoogle Scholar
  23. 23.
    Stoch SA, Parker RA, Chen L, Bubley G, Ko Y, Vincellette A, Greenspan SL. (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787–2791.CrossRefPubMedGoogle Scholar
  24. 24.
    Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE, Mcleod DG. (2002) Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prost Cancer Prost Dis 5:304–310.CrossRefGoogle Scholar
  25. 25.
    Pickett M, Bruner DW, Joseph A, Burgraf V. (2000) Prostate cancer elder alert: living with treatment choices and outcomes. J Gerontol Nurs 26:22–34.PubMedGoogle Scholar
  26. 26.
    Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ, Kennealey GT. (1992) Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res 1:323–330.CrossRefPubMedGoogle Scholar
  27. 27.
    Cleary PD, Morrissey G, Oster G. (1995) Health-related quality of life in patients with advanced prostate cancer. Qual Life Res 4:207–220.CrossRefPubMedGoogle Scholar
  28. 28.
    Alibhai SMH, Rahman S, Warde PR, Jewett MA, Jaffer T, Cheung AM. (2006) Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology 68:126–131.CrossRefPubMedGoogle Scholar
  29. 29.
    Basaria S, Lieb JI, Tang§ AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS. (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrin 56:779–786.CrossRefGoogle Scholar
  30. 30.
    Soyupek F, Soyupek H, Ozorak A. (2008) Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol 26:141–146.PubMedGoogle Scholar
  31. 31.
    Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. (2006) Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. Br J Urol Int 98:20–27.Google Scholar
  32. 32.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512.CrossRefPubMedGoogle Scholar
  33. 33.
    Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock IF. (2008) Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763–2767.CrossRefPubMedGoogle Scholar
  34. 34.
    Picus J, Schultz M. (1999) Docetaxel (taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary Results. Semin Oncol 26:14–18.PubMedGoogle Scholar
  35. 35.
    Casperson CJ, Powell KE, Christenson GM. (1985) Physical activity, exercise, and physical fitness: definition and distinctions for health-related research. Public Health Rep 100:126–131.Google Scholar
  36. 36.
    Bouchard C, Shephard RJ, Physical Activity, Fitness, and Health: International Proceedings and Consensus Statement. Physical activity, fitness, and health: the model and key concepts, Windsor, ON: Human Kinetics, 1994, 77–88.Google Scholar
  37. 37.
    Paffenbarger RS, Hyde RT, Wing AL, Hsieh CC. (1986) Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med 314:605–613.CrossRefPubMedGoogle Scholar
  38. 38.
    Warburton DER, Nicol CW, Bredin SSD. (2006) Health benefits of PA: the evidence. Can Med Assoc J 174:801–809.CrossRefGoogle Scholar
  39. 39.
    Kampert JB, Blair SN, Barlow CE, Kohl HW III, Harold W. (1996) Physical activity, physical fitness, and all-cause and cancer mortality: a prospective study of men and women. Ann Epidemiol 6:452–457.CrossRefPubMedGoogle Scholar
  40. 40.
    Friedenreich CM, Thune I. (2001) A review of PA and prostate cancer risk. Cancer Causes Control 12:461–475.CrossRefPubMedGoogle Scholar
  41. 41.
    Min LI-. (2003) Physical activity and cancer prevention-data from epidemiologic studies. Med Sci Sports Exerc 35:1823–1827.CrossRefGoogle Scholar
  42. 42.
    Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ Willett WC. (2005) A prospective study of PA and incident and fatal prostate cancer. Arch Intern Med 165:1005–1010.CrossRefPubMedGoogle Scholar
  43. 43.
    Tymchuk CN, Barnard RJ, Heber D, Aronson WJ. (2001) Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. J Urol 166:1185–1189.CrossRefPubMedGoogle Scholar
  44. 44.
    Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ. (2002) Effect of diet and exercise on serum insulin, IFG-I, and IFGBP-1 levels and growth of LNCaP cells in vitro. Cancer Causes Control 13:929–935.CrossRefPubMedGoogle Scholar
  45. 45.
    Galvão DA, Taaffe DR, Spry N, Newton RU. (2007) Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prost Cancer Prost Dis 8:1–7.Google Scholar
  46. 46.
    Ngo TH, Barnard RJ, Leung P, Cohen P, Aronson WJ. (2003) Insulin-like growth factor (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144:2319–2324.CrossRefPubMedGoogle Scholar
  47. 47.
    Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. (2003) A low-fat diet and/or strenuous exercise alters the IFG axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 56:201–206.CrossRefPubMedGoogle Scholar
  48. 48.
    Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. (2004) Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol 96:450–454.CrossRefPubMedGoogle Scholar
  49. 49.
    Tymchuk CN, Tessier SB, Aronson WJ, Barnard RJ. (1998) Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 31:127–131.CrossRefPubMedGoogle Scholar
  50. 50.
    Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA. (2007) A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. Eur J Cancer Prev 16:415–421.CrossRefPubMedGoogle Scholar
  51. 51.
    Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D’Angelo ME, Wells GA. (May 1. 2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659.CrossRefPubMedGoogle Scholar
  52. 52.
    Segal RJ, Reid R, Proulx C, Courneya K, Sigal R, Kenny G, Prud’homme S, Wells MG, (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation for prostate cancer. Journal of Clinical Oncology. 27: 344–351.CrossRefPubMedGoogle Scholar
  53. 53.
    Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Kanemitsu Y, Newton RU. (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38:2045–2052.CrossRefPubMedGoogle Scholar
  54. 54.
    Duke University Medical Center. (2008) Exercise May Lead to Faster Prostate Tumor Growth, April 14, 2008.Google Scholar
  55. 55.
    Thorsen L, Courneya KS, Stevinson C, Fossa SD. (2008) A systematic review of PA in prostate cancer survivors: outcomes, prevalence, and determinants. Supportive Care Cancer 16:987–997.CrossRefGoogle Scholar
  56. 56.
    Durak EP, Harris J, Ceriale SM. (2001) The effects of exercise on quality of life improvement in cancer survivors: the Results of a national survey. J Exerc Online 4:21–28.Google Scholar
  57. 57.
    Stevinson C, Lawlor D, Fox K. (2004) Exercise interventions for cancer patients: systematic review of controlled trials. Cancer Causes Control 15:1035–1056.CrossRefPubMedGoogle Scholar
  58. 58.
    Freedland SJ, Krupski TL, Moul JW. (2006) Update on outcomes research databases in prostate cancer 2006. Curr Opin Urol 16:168–172.CrossRefPubMedGoogle Scholar
  59. 59.
    Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, Terris MK. (2004) Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group. J Clin Oncol 22:446–453.CrossRefPubMedGoogle Scholar
  60. 60.
    Chang SS, Duong DT, Wells N, Cole EE, Smith JA, Cookson MS. (2004) Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. J Urol 171:1861–1865.CrossRefPubMedGoogle Scholar
  61. 61.
    Windsor PM, Nicol KF, Potter J. (2004) A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 101:550–557.CrossRefPubMedGoogle Scholar
  62. 62.
    Monga U, Garber SL, Thornby J, Vallbona C, Kerrigan A, Monga TN, Zimmerman KP. (2007) Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil 88:1416–1422.CrossRefPubMedGoogle Scholar
  63. 63.
    Smith JA, Jr. Soloway MS, Young MJ. (1999) Complications of advanced prostate cancer. Urology 54:8–14.CrossRefPubMedGoogle Scholar
  64. 64.
    Williams MB, Hernandez J, Thompson I. (2005) Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol 173:1067–1071.CrossRefPubMedGoogle Scholar
  65. 65.
    Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL. (2007) Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther 87:1325–1333.CrossRefPubMedGoogle Scholar
  66. 66.
    Breunis H, Leach M, Naglie G, Tannock IF, Fleshner NE, Krahn M, Duff-Canning S, Tomlinson G, Warde P, Alibhai SM. (2008) Androgen deprivation therapy (ADT) and physical function in men with nonmetastatic prostate cancer. J Clin Oncol 27:4895.Google Scholar
  67. 67.
    Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. (2002) Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Nat Cancer Inst 94:430–437.PubMedGoogle Scholar
  68. 68.
    Daniell HW. (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439–444.CrossRefPubMedGoogle Scholar
  69. 69.
    Lee H, McGovern K, Finkelstein JS, Smith MR. (2005) Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104:1633–1637.CrossRefPubMedGoogle Scholar
  70. 70.
    Shahinian VB, Yong-Fang K, Freeman JL, Goodwin JS. (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164.CrossRefPubMedGoogle Scholar
  71. 71.
    Oeffelein MG, Ricchuiti V, Conrad W, Resnick M. (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005–1007.CrossRefGoogle Scholar
  72. 72.
    Carmack Taylor CL, Demoor C, Smith MA, Dunn AL, Basen-Engquist K, Nielsen I, Pettaway C, Sellin R, Massey P, Gritz ER. (2006) Active for life after cancer: A randomized trial examining a lifestyle PA program for prostate cancer patients. Psycho-Oncology 15:847–862.CrossRefPubMedGoogle Scholar
  73. 73.
    Prochaska JO, Velicer WF. (1997) The transtheoretical model of health behavior change. Am J Health Prom 12:38–48.Google Scholar
  74. 74.
    Prochaska JO, DiClemente CC. (1983) Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 51:390–395.CrossRefPubMedGoogle Scholar
  75. 75.
    Bandura A. (1986) Social foundations of thought and action: a social cognitive theory. Prentice Hall, Englewood Cliffs, NJ.Google Scholar
  76. 76.
    Bandura A. (1997) Self-efficacy: the exercise of control. W.H. Freeman and Company, New York.Google Scholar
  77. 77.
    Culos-Reed SN, Robinson JL, Lau H, O‘Connor K, Keats MR. (2007) Benefits of a PA intervention for men with prostate cancer. J Sport Exerc Psych 29:118–127.Google Scholar
  78. 78.
    Courneya KS, Friedenreich CM. (Fall 1997) Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. J Altern Complement Med 3:215–226.CrossRefPubMedGoogle Scholar
  79. 79.
    Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M, Norris S, Kline G. (2007) Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention Support Canre Cancer. 17 (online).Google Scholar
  80. 80.
    Berglund G, Bolund C, Gustafsson UL, Sjoden PO. (1994) A randomized study of a rehabilitation program for cancer patients: the ‘starting again’ group. Psycho-Oncology 3:109–120.CrossRefGoogle Scholar
  81. 81.
    Berglund G, Bolund C, Gustafsson UL, Sjoden PO. (1994) One-year follow-up of the ‘starting again’ group rehabilitation programme for cancer patients. Eur J Cancer 30A:1744–1751.CrossRefPubMedGoogle Scholar
  82. 82.
    Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. (2005) Physical exercise in cancer patients during and after medical treatment: A systematic review of randomized and controlled clinical trials. J Clin Oncol 23:3830–3842.CrossRefPubMedGoogle Scholar
  83. 83.
    Courneya KS, Segal RJ, Reid RD, Jones LW, Malone SC, Venner PM, Parliament MB, Scott CG, Quinney HA, Wells GA. (2004) Three independent factors predicted adherence in a randomized controlled trial of exercise training among prostate cancer survivors. J Clin Epidem 57:571–579.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Daniel Santa Mina
    • 1
  • Paul Ritvo
    • 2
  • Roanne Segal
    • 3
  • N. Culos-Reed
    • 4
  • Shabbir M.H. Alibhai
    • 5
  1. 1.Department of Surgical OncologyUniversity Health NetworkTorontoCanada
  2. 2.Population Studies and SurveillanceCancer Care Ontario, University AvenueTorontoCanada
  3. 3.Ottawa Hospital Regional Cancer Center, University of Ottawa Heart InstituteOttawaCanada
  4. 4.Department of KinesiologyDalhousie UniversityHalifaxCanada
  5. 5.Division of Clinical Decision Making and HealthcareToronto General Research Institute, Toronto General HospitalTorontoCanada

Personalised recommendations